downloadDownload

Interest of PET as an imaging biomarker of a personalized treatment by targeted therapy and hormonotherapy in patients with estrogen receptor alpha (ER) negative breast carcinoma.

assignment_turned_inproject30 Jul 2011(Started)-29 Jul 2014(Ended)Closed

Funder: Institut National du CancerProject code: INCa-4010 Call for proposal: TRANSLA11

Funded under: TRANSLA

Interest of PET as an imaging biomarker of a personalized treatment by targeted therapy and hormonotherapy in patients with estrogen receptor alpha (ER) negative breast carcinoma.

- Summary
- DMPs

Partners

Institut Claudius Regaud , INSERM U563

Data Management Plans

Start a new DMP in Argos

Select content type to embed

All Research products

arrow_drop_down

<script type="text/javascript">
<!--
document.write('<div id="oa_widget"></div>');
document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=inca________::813afcc9ed34d137983248fef84ce829&type=result"></script>');
-->
</script>

COPY SCRIPT

For further information contact us at helpdesk@openaire.eu

Interest of PET as an imaging biomarker of a personalized treatment by targeted therapy and hormonotherapy in patients with estrogen receptor alpha (ER) negative breast carcinoma.

Interest of PET as an imaging biomarker of a personalized treatment by targeted therapy and hormonotherapy in patients with estrogen receptor alpha (ER) negative breast carcinoma.

Loading